Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390488 | 0.82 | CYP1A2 (0.70) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL387105 | 0.79 | SMN1; SMN2 (0.73) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL391381 | 0.76 | CYP1A2 (0.60) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL3631097 | 0.75 | CYP1A2 (0.59) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL386861 | 0.75 | CYP1A2 (0.60) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL27747875 | 0.75 | CYP1A2 (0.59) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL391000 | 0.74 | CYP1A2 (0.59) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL29656815 | 0.74 | CYP1A2 (1.00) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL390553 | 0.74 | CYP1A2 (0.58) | CYP1A2GPR119ALDH1A1GAAHSD17B10 | |
| SCHEMBL11504585 | 0.73 | CYP1A2 (0.57) | CYP1A2GPR119ALDH1A1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | CYP1A2 2735/4885GPR119 1/4885ALDH1A1 2608/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | CYP1A2 2735/4885GPR119 1/4885ALDH1A1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.